FavipiravirThird Party Manufacturing in India

Favipiravir works as a selective inhibitor of viral RNA-dependent RNA polymerase (RdRp). It is a prodrug that is converted intracellularly by host cell enzymes into its active ribofuranosyl-5-triphosphate (favipiravir-RTP) form. The structural similarity of favipiravir-RTP to natural purine nucleotides allows it to compete with them during viral RNA replication. It is incorporated into the growing viral RNA strand by the RdRp enzyme, which leads to the termination of viral RNA elongation.

In addition to chain termination, the incorporation of favipiravir-RTP induces lethal mutagenesis in the virus. This process introduces multiple transition mutations into the viral genome, resulting in non-viable viral offspring and preventing further viral replication. Because the host cell's DNA and RNA polymerases are highly selective, favipiravir-RTP does not inhibit human cell genetic processes, making it a highly selective antiviral agent against RNA viruses.

Our services for Favipiravir third party manufacturing in India supply high-quality tablets in multiple strengths to meet the requirements of retail and institutional distributors globally.

Therapeutic Uses

Favipiravir tablets are prescribed for the treatment of:

• Novel or Pandemic Influenza: Approved for treating influenza virus infections unresponsive or resistant to standard anti-influenza therapies.
• Severe Acute Respiratory Infections: Utilized in various countries for the management of viral pneumonia, including SARS-CoV-2 (COVID-19) under emergency use authorization.
• Viral Hemorrhagic Fevers: Researched and utilized in clinical trials for treating infections caused by Ebola virus, Lassa virus, and Hantaviruses.
• Emerging RNA Viruses: Administered as an investigational agent for other high-consequence RNA viral infections, such as Nipah and West Nile viruses.

Why Manufacturers Choose Favipiravir

Favipiravir has gained significant global attention as a broad-spectrum antiviral agent due to its target, the viral RdRp enzyme, which is highly conserved across various RNA viruses. This makes it an essential compound for emergency preparedness and pandemic planning. The formulation of oral tablets in 200mg, 400mg, and 800mg strengths is a cost-effective, easily distributable option for large-scale public health programs.

For PCD franchise companies and export agencies, Favipiravir tablets represent a critical addition to their respiratory and infectious disease portfolios. Indian manufacturing facilities produce these tablets using state-of-the-art solid dosage machinery under strict WHO-GMP compliance, ensuring the highest standards of safety and efficacy. Read more on our contract manufacturing page, search our manufacture listing, or contact us to receive a custom batch quote.